Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2013
03/28/2013US20130078241 Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same
03/28/2013US20130078240 4-1bb binding molecules
03/28/2013US20130078238 Methods and Compositions for Treating Hepatitis with Anti-CD3 Immune Molecule Therapy
03/28/2013US20130078237 Cd27l antigen binding proteins
03/28/2013US20130078232 Compositions and methods useful for stabilizing protein-containing formulations
03/28/2013US20130078216 Liver targeting molecules
03/28/2013US20130078183 Multiple Signaling Pathways Induced by Hexavalent, Monospecific and Bispecific Antibodies for Enhanced Toxicity to B-Cell Lymphomas and Other Diseases
03/28/2013US20130078182 Structural Variants of Antibodies for Improved Therapeutic Characteristics
03/28/2013DE102011118015A1 IgY-Zusammensetzung für die Verwendung in der Zöliakie IgY composition for use in the celiac
03/28/2013DE102011083595A1 Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose Inhibition of the effect of interleukin 1 beta for the treatment of endometriosis
03/28/2013CA2849822A1 Novel influenza hemagglutinin protein-based vaccines
03/28/2013CA2849710A1 Cachexia treatment
03/28/2013CA2849705A1 Modified albumin-binding domains and uses thereof to improve pharmacokinetics
03/28/2013CA2849562A1 Vegf/dll4 binding agents and uses thereof
03/28/2013CA2849434A1 Influenza virus vaccines and uses thereof
03/28/2013CA2849409A1 Anti-tumor necrosis factor-alpha agents and uses thereof
03/28/2013CA2849374A1 Vaccibodies targeted to cross-presenting dendritic cells
03/28/2013CA2849318A1 Cd27l antigen binding proteins
03/28/2013CA2849259A1 Cancer immunotherapy
03/28/2013CA2849195A1 Prolonged inhibition of interleukin-6 mediated signaling
03/28/2013CA2848510A1 Combination therapy using immunoglobulin and c1-inhibitor
03/28/2013CA2848471A1 Modified gram positive bacteria and uses thereof
03/28/2013CA2848346A1 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
03/28/2013CA2846630A1 Combination treatments comprising c-met antagonists and b-raf antagonists
03/28/2013CA2846062A1 Shigella-derived vector and methods of using the same
03/28/2013CA2843019A1 Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
03/27/2013EP2573186A1 Methods of producing influenza vaccine compositions
03/27/2013EP2573185A2 Lentiviral vectors and their use
03/27/2013EP2573175A2 ANTIBODY CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING ANTIPROLIFERATIVE ACTIVITY ON CANCER HAVING Ras GENE MUTATION
03/27/2013EP2573166A2 Methods for preparing T-cells for cell therapy
03/27/2013EP2573121A1 Antibodies that bind il-4 and/or il-13 and their uses
03/27/2013EP2573120A1 Anti-human trop-2 antibody having anti-tumor activity in vivo
03/27/2013EP2573114A1 Identification and engineering of antibodies with variant Fc regions and methods of using same
03/27/2013EP2573112A1 Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
03/27/2013EP2573110A2 Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens
03/27/2013EP2573109A2 Peptide vaccines comprising Seq Id 101, 80 or 100 for cancers expressing tumor-associated antigens
03/27/2013EP2573105A1 P16 inka4a derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16 ink4a expressing tumors
03/27/2013EP2572734A2 Cytokine-based fusion proteins for treatment of immune disorders
03/27/2013EP2572730A1 Method for prevention or treatment of metabolic syndrome
03/27/2013EP2572729A2 High affinity human antibodies to human nerve growth factor
03/27/2013EP2572728A1 Duck embryonic derived stem cell lines for the production of viral vaccines
03/27/2013EP2572727A1 Duck embryonic derived stem cell lines for the production of viral vaccines
03/27/2013EP2572726A1 Compositions comprising pneumococcal antigens
03/27/2013EP2572725A1 MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
03/27/2013EP2572715A1 Immunostimulatory Combinations
03/27/2013EP2572714A1 Immunostimulatory Combinations
03/27/2013EP2572707A2 Microparticles with adsorbed polypeptide-containing molecules
03/27/2013EP2572002A1 Method for detection of predisposition to atherosclerosis, coronary heart disease and related conditions
03/27/2013EP2571990A2 Universal dengue virus sequences and methods of use
03/27/2013EP2571982A1 Antigen specific tregs and related compositions, methods and systems
03/27/2013EP2571980A1 Methods relating to an attenuated mycoplasma
03/27/2013EP2571979A1 Bacterial ribonucleic acid cell wall compositions and methods of making and using them
03/27/2013EP2571901A1 Biological materials related to her3
03/27/2013EP2571898A2 High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
03/27/2013EP2571577A1 Improved immunotherapeutic dosing regimens and combinations thereof
03/27/2013EP2571532A2 Il-1 binding proteins
03/27/2013EP2571523A2 Latent human immunodeficiency virus reactivation
03/27/2013EP2571522A2 Cancer treatment
03/27/2013EP2571521A1 Parapoxvirus vectors containing rabies virus antigen
03/27/2013EP2571520A1 Influenza virus reassortment method
03/27/2013EP2571519A1 Marker vaccine for classical swine fever
03/27/2013EP2571518A1 Mycobacterial antigen composition
03/27/2013EP2571513A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
03/27/2013CN1961003B Humanized anti-TGF-beta antibodies
03/27/2013CN1913920B Influenza immunogen and vaccine
03/27/2013CN1370083B Ninovasive genetic immnization, expression products therefrom, and uses thereof
03/27/2013CN1259141B PRRSV antigenic sites identifying peptide sequences of PRRS virus for use in vaccines or diagnostic assays
03/27/2013CN103003695A Method for detecting malignant tumor cells
03/27/2013CN103003427A Novel nucleic acid having adjuvant activity and use thereof
03/27/2013CN103003424A Antibody capable of binding to transforming growth factor alpha and having antiproliferative activity on cancer having Ras gene mutation
03/27/2013CN103003309A Superior efficacy of CD37 antibodies in CLL blood samples
03/27/2013CN103003307A Monoclonal antibodies against c-Met
03/27/2013CN103003306A Antibodies
03/27/2013CN103003305A 癌症疫苗 Cancer vaccine
03/27/2013CN103003304A Prophylaxis of colorectal and gastrointestinal cancer
03/27/2013CN103003302A Humanized and chimeric anti-properdin antibodies
03/27/2013CN103002919A Tumor targeted delivery of immunomodulators by nanoplymers
03/27/2013CN103002916A Novel anti-cmet antibody
03/27/2013CN103002915A Methods and compositions for inhibition of Treg cells
03/27/2013CN103002914A Compositions and methods for inhibiting MMSET
03/27/2013CN103002913A Compositions and methods for targeting type I interferon producing cells
03/27/2013CN103002912A Antibodies against the ectodomain of ErbB3 and uses thereof
03/27/2013CN103002911A Frizzled-binding agents and uses thereof
03/27/2013CN103002910A Vaccine composition
03/27/2013CN103002909A Pharmaceutical compositions comprising a polypeptide comprising at least one CXXC motif and heterologous antigens and uses thereof
03/27/2013CN103002908A Mucosal vaccine
03/27/2013CN103002907A Eczema treatment
03/27/2013CN103002905A Use of the SPARC microenvironment signature in the treatment of cancer
03/27/2013CN102994520A Infectious bursal disease VP2 gene and application thereof
03/27/2013CN102994515A Allogeneic tumor therapeutic agent
03/27/2013CN102994508A Olmsted syndrome related gene identification, identification product, identification method, and use of identification
03/27/2013CN102994460A Infectious bronchitis virus attenuated vaccine strain
03/27/2013CN102994458A Porcine pseudorabies virus virulent strain, and gene deletion vaccine strain thereof and applications thereof
03/27/2013CN102993313A GM-CSF-TAT-CEA recombinant protein, method and application thereof
03/27/2013CN102993312A GM-CSF-HER2 recombinant protein, method and application thereof
03/27/2013CN102993311A Infusion protein of IDB (Infectious Bursal Disease) virus VP2 protein and LTB (Leukotrienes B) and application thereof
03/27/2013CN102993310A Fusion protein of IBD (Infectious Bursal Disease) VP2 and IL (Interleukin)-2 and application thereof
03/27/2013CN102993308A Methicillin-resistant staphylococcus aureus (MRSA) vaccine recombinant protein antigen HI2 and preparation method and application thereof
03/27/2013CN102993306A High affinity, anti-human IgE antibodies
03/27/2013CN102993305A Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof
1 ... 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 ... 1823